Cryptococcal Meningitis

• Polysaccharide capsule-mediated immune evasion: Cryptococcus neoformans produces an antiphagocytic polysaccharide capsule composed primarily of glucuronoxylomannan (GXM) and galactoxylomannan. This capsule is poorly immunogenic and actively suppresses host immune responses through multiple mechanisms: (1) molecular mimicry with host neural tissue reduces immune recognition; (2) the capsule sheds into serum and cerebrospinal fluid (CSF), creating a decoy that absorbs complement and antibodies, preventing them from reaching the organism; (3) GXM directly suppresses T-cell proliferation and Th1 differentiation, favoring an immunosuppressive Th2 response. In immunocompetent hosts, the capsule is still recognized but triggers slower granuloma formation. In severely immunosuppressed patients (CD4 <50 cells/μL), minimal granulomatous response occurs, allowing uninhibited organism proliferation and high organism burden.

• Blood-brain barrier disruption and CNS invasion: Cryptococcus disseminates hematogenously after pulmonary acquisition and crosses the blood-brain barrier through poorly understood mechanisms involving transcytosis across endothelial cells and, less commonly, through infected monocytes ("Trojan horse" mechanism). Once CNS infection is established, the organism induces localized inflammation through toll-like receptor activation and mannan recognition, leading to increased vascular permeability, cerebral edema, and elevation of intracranial pressure (ICP). The polysaccharide-rich CSF becomes gelatinous, impeding normal CSF flow and absorption, creating a physical obstruction that compounds elevated ICP. Paradoxically, the minimal inflammatory response in deeply immunosuppressed patients results in a lower CSF white blood cell (WBC) count, making CSF analysis less dramatically abnormal despite massive organism burden—a diagnostic pitfall.

• Immune reconstitution inflammatory syndrome (IRIS) pathophysiology: Following antiretroviral therapy (ART) initiation in advanced AIDS patients, immune recovery permits recognition of cryptococcal antigen and organisms by newly resurgent T-cell and innate immune responses. This paradoxical clinical deterioration, occurring 2–12 weeks after ART initiation, results from heightened inflammatory responses to persistent cryptococcal antigens and organisms. CD4+ T-cell recovery enables IFN-γ production and macrophage activation, amplifying granuloma formation and CNS inflammation, potentially causing paradoxical CSF inflammation with increased WBC counts, new or enlarging cryptococcomas, and vasculitis. IRIS is distinguished from treatment failure by immune reconstitution markers (CD4 recovery) and CSF sterilization despite clinical worsening.

• Cryptococcoma formation and mass effect: In some patients, particularly those with higher baseline CD4 counts, Cryptococcus can form localized granulomatous masses (cryptococcomas) visible on neuroimaging. These lesions represent organized granulomatous responses with central yeast and surrounding inflammatory cells. Cryptococcomas can enlarge paradoxically during immune reconstitution and cause mass effect, obstructive hydrocephalus, or seizures through their space-occupying effect independent of infectious burden.

• Elevated intracranial pressure mechanisms: Multiple factors drive ICP elevation: (1) cerebral edema from CNS inflammation and blood-brain barrier disruption; (2) impaired CSF absorption due to arachnoiditis and thickened, gelatinous CSF; (3) vasculitis affecting cerebral vessels; (4) hydrocephalus from communicating obstruction by inflammatory exudate. ICP elevation occurs even in patients with minimal CSF pleocytosis, representing a major cause of morbidity and mortality. Progressive ICP elevation causes headache, confusion, and altered mental status, ultimately leading to transtentorial herniation if untreated.

• HIV/AIDS with advanced immunosuppression (CD4 <100 cells/μL): This is the predominant risk factor globally, accounting for >90% of cases in endemic regions. The incidence increases dramatically as CD4 count falls below 100 cells/μL; patients with CD4 <50 cells/μL face an annual risk of 5–10% in the absence of antifungal prophylaxis. CMis often the AIDS-defining illness. Risk escalates further with concurrent opportunistic infections, malnutrition, and delayed ART initiation. In developed countries with widespread ART access, CM incidence has declined significantly but remains a common cause of meningitis in patients with unrecognized or untreated HIV.

• Chronic corticosteroid use and other causes of T-cell immunosuppression: High-dose corticosteroid therapy (typically ≥20 mg prednisone daily for >3 weeks) increases CM risk substantially, particularly when combined with other immunosuppressive conditions. Solid organ and hematopoietic stem cell transplant recipients (absolute CD4 nadir often <50 cells/μL during conditioning) face significant risk. Patients receiving TNF-α inhibitors for rheumatologic diseases demonstrate increased susceptibility, particularly with concurrent immunosuppression. Hematologic malignancies, especially hematologic cancers receiving intensive chemotherapy, predispose to CM through multiple mechanisms of immune dysfunction.

• **Environmental exposure to *Cryptococcus neoformans***: Inhalation of spores from contaminated soil, bird droppings (especially pigeons), and decaying vegetation initiates infection. Geographic clustering occurs in certain regions (higher prevalence in tropical and subtropical climates), but Cryptococcus is distributed worldwide. Initial pulmonary infection is usually asymptomatic or minimally symptomatic; dissemination to the CNS occurs during periods of profound immunosuppression. Patients with occupational exposure (agricultural workers, construction workers) may have increased baseline risk.

• Diabetes mellitus and other metabolic conditions: Type 2 diabetes mellitus increases risk through impairment of neutrophil and T-cell function. Severe diabetes with poor glycemic control further amplifies risk. End-stage renal disease and uremia reduce immune function and increase infection risk independent of CD4 count status.

• Primary versus secondary prophylaxis context: Primary prophylaxis (in HIV patients with CD4 <50 cells/μL) prevents initial infection. Secondary prophylaxis (maintenance therapy after treatment of active disease) prevents relapse in patients not receiving ART or with poor CD4 recovery.

• Headache (subacute onset, often the cardinal symptom): Develops insidiously over days to weeks, distinguishing CM from bacterial meningitis. The headache is typically bifrontal or generalized, nonthrobbing, and may be relatively mild despite serious underlying disease. Severity does not correlate with CSF findings or organism burden—a critical diagnostic point. Headache results from combination of meningeal inflammation, elevated ICP, and vasculitis. In deeply immunosuppressed patients, headache may be the only presenting symptom, and its absence should not reduce suspicion if other features are present.

• Fever (present in 50–80% of cases, often low-grade or absent in severely immunosuppressed): Paradoxically, profound immunosuppression may result in minimal fever response despite heavy organism burden, making fever absence unhelpful for exclusion. When present, fever is typically low-grade (38–39°C) and may wax and wane. High fever should prompt consideration of concurrent bacterial infection or other CNS pathogens.

• Altered mental status and cognitive dysfunction (in 40–50% of patients): Ranges from subtle personality changes and mild confusion to profound encephalopathy, delirium, and coma. Confusion may develop insidiously, making timing difficult for patients or families to specify. Encephalopathy results from elevated ICP, metabolic derangements, and direct CNS inflammation. Progressive lethargy culminating in unresponsiveness heralds herniation risk without intervention.

• Nuchal rigidity and meningeal signs (notably absent or minimal in ~40% of cases): Classical meningeal signs (neck stiffness, Kernig sign, Brudzinski sign) may be entirely absent, particularly in patients with CD4 counts <50 cells/μL where minimal inflammatory response occurs. When present, nuchal rigidity is usually mild and may not appear until several days into illness. Absence of meningeal signs should never exclude CM from the differential diagnosis, particularly in deeply immunosuppressed patients presenting with subacute headache.

• Cryptococcal antigenemia as marker of dissemination: Serum cryptococcal antigen (CrAg) positivity indicates disseminated disease with high organism burden and CNS involvement. CrAg is present in >99% of patients with CM but also appears in cryptococcemia without CNS disease (pulmonary only). CrAg positivity in a patient with headache has very high post-test probability of CM when combined with CSF findings.

• Visual symptoms and photophobia (variable presence): Photophobia may be present but is often mild or absent compared to bacterial meningitis, another diagnostic point favoring CM over other causes. Visual disturbances may result from raised ICP causing cranial nerve compression or from vasculitis affecting posterior circulation. Visual symptoms should increase suspicion for hydrocephalus, mass effect, or complications like cryptococcomas.

• Seizures (5–10% of presentations, rising with complications): Seizures occur more commonly during immune reconstitution or with cryptococcomas causing cortical irritation. Seizures may herald increased ICP or stroke from vasculitis. First seizure in a CM patient warrants immediate neuroimaging to assess for complications.

• Atypical presentations in severely immunosuppressed patients: In patients with CD4 <20 cells/μL, CM may present with minimal constitutional symptoms, subtle cognitive changes only, or incidental finding on CSF analysis performed for other indications. Some patients present with isolated headache lasting weeks to months before diagnosis. Others present with direct complications (obstructive hydrocephalus, stroke) as the initial manifestation.

• Pulmonary symptoms (uncommon in pure CNS disease): Respiratory symptoms are infrequent in CNS-only disease but should raise suspicion for concurrent pulmonary cryptococcosis. Cough, dyspnea, or infiltrates on imaging suggest pulmonary involvement.

• CSF analysis with India ink microscopy and fungal culture (gold standard):
• India ink staining detects ~50–80% of CM cases by visualizing the polysaccharide capsule as a clear halo around the organism; sensitivity is higher in patients with CD4 >100 cells/μL (more inflammatory response) and lower in deeply immunosuppressed patients (<50 cells/μL) where organism burden despite high fungal burden. India ink positivity is specific (~99%) but cannot be relied upon for exclusion due to sensitivity limitations.
• CSF fungal culture remains the gold standard, with positive cultures in >95% of untreated CM cases. Cultures typically become positive within 1–2 weeks but may require prolonged incubation (up to 4 weeks in some labs). Culture permits organism identification, antifungal susceptibility testing (increasingly important for detecting amphotericin B-resistant strains), and provides definitive diagnosis. Culture negativity does not exclude CM if clinical and other laboratory features support diagnosis.

• CSF cryptococcal polysaccharide antigen (CrAg) testing (highly sensitive and specific):
• CSF CrAg is positive in >99% of CM cases and is the fastest diagnostic test (results within hours). Sensitivity approaches 100% even in patients with CD4 <50 cells/μL, making it superior to India ink and the preferred initial test. CSF CrAg positivity has positive predictive value >95% for CM when clinical context is appropriate. False positives are rare (<1%) but can occur with contamination. Negative CSF CrAg effectively excludes CM as a diagnosis.
• Serum CrAg positivity (present in >95% of CM cases) indicates disseminated disease but does not confirm CNS involvement, as serum CrAg can be positive in pulmonary-only cryptococcosis. However, serum CrAg should always be checked, and positive serum CrAg combined with appropriate CSF findings makes CM diagnosis highly probable.

• CSF cell count and biochemistry (supportive but nondiagnostic):
• In patients with CD4 >100 cells/μL, CSF typically shows lymphocytic pleocytosis with 10–500 cells/μL (range 0–1000), predominantly lymphocytes with normal to slightly elevated protein (50–500 mg/dL) and normal to low glucose (often hypoglycorrhachia <40 mg/dL or CSF:serum glucose ratio <0.5).
• In deeply immunosuppressed patients (CD4 <50 cells/μL), CSF may show minimal pleocytosis (0–20 cells/μL or even acellular) despite massive organism burden, creating a diagnostic trap. This "acellular meningitis" with minimal inflammation can delay diagnosis if CrAg is not performed. Protein may be only mildly elevated, and glucose can be normal.
• Markedly elevated CSF protein (>100 mg/dL with mild pleocytosis) or very low glucose suggests alternative diagnoses (tuberculosis, partially treated bacterial meningitis).

• Serum and CSF cryptococcal antigen testing (CrAg ELISA or latex agglutination):
• Serum CrAg is positive in >95% of CM cases; positive serum CrAg in an HIV patient with headache and CSF abnormalities has high specificity for CM. Serum CrAg testing is more sensitive than CSF testing for detecting disseminated disease (some patients have positive serum but negative CSF antigen, though this is uncommon in pure CNS disease).
• The combination of positive serum CrAg + positive CSF CrAg + compatible CSF findings confirms CM diagnosis with >99% probability.

• Neuroimaging (CT or MRI):
• MRI is preferred over CT for superior sensitivity in detecting CNS cryptococcal disease. Imaging findings are variable and nonspecific:
• Meningeal enhancement: Minimal or absent in most CM cases, contrasting with bacterial meningitis. When present, enhancement is typically basilar and subtle. Lack of enhancement does not exclude CM.
• Gelatinous exudate: Thickened, gelatinous appearance in basal cisterns or ventricles due to polysaccharide-rich CSF, seen as hyperintense signal in subarachnoid spaces on T1-weighted imaging.
• Cryptococcomas: Well-circumscribed nodular lesions (0.5–10 mm), appearing as hypodense lesions on CT or T2-hyperintense lesions on MRI, typically without surrounding edema and without significant enhancement. Cryptococcomas occur in 5–10% of cases and may enlarge paradoxically during immune reconstitution.
• Hydrocephalus: Ventricular dilatation occurs when gelatinous exudate obstructs CSF flow, particularly at the foramen of Monro or basal cisterns.
• Cerebral edema: Generalized or localized edema may indicate elevated ICP.
• Imaging is essential for excluding alternative diagnoses (hemorrhage, infarction, mass lesions) and assessing for complications (hydrocephalus, mass effect). Imaging findings should never delay CSF analysis and CrAg testing.

• Diagnostic criteria and algorithm:
• Definitive diagnosis: Positive CSF fungal culture OR positive CSF CrAg in patient with compatible clinical presentation (headache, CNS symptoms) and CSF abnormalities.
• Probable diagnosis: Positive serum CrAg + positive CSF CrAg + compatible clinical features, even if culture and India ink are negative.
• Possible diagnosis: Positive serum CrAg in clinical context of headache with CSF abnormalities but negative CSF CrAg (rare; consider contamination or technical issue before accepting negative CSF CrAg).
• Diagnostic algorithm: In HIV patient with CD4 <100 cells/μL presenting with headache, perform immediate CSF analysis including CrAg testing; if CSF CrAg is positive, begin antifungal therapy without

Immediate stabilization — intracranial pressure is treated in parallel with the fungus

• Measure the opening pressure at the diagnostic LP — this is a management step, not just a diagnostic one. Per the IDSA cryptococcal disease guideline, an opening pressure ≥25 cm H₂O warrants therapeutic CSF drainage at the same sitting, removing volume to reduce pressure by roughly half (or to normal), with daily repeat LPs until pressure and symptoms stabilize. Uncontrolled ICP, not fungal burden, is the leading early killer.

Induction (≥2 weeks)

• Polyene + pyrimidine analogue: amphotericin B plus flucytosine is the induction backbone. Amphotericin binds ergosterol and punches pores in the fungal membrane; flucytosine is deaminated by fungal cytosine deaminase (absent in humans) to 5-FU, blocking fungal DNA/RNA synthesis. This pairing achieves the fastest CSF sterilization and the lowest mortality of available induction regimens.
• Which polyene: the 2010 IDSA cryptococcal guideline lists amphotericin B deoxycholate (0.7–1 mg/kg/day) plus flucytosine as standard induction, with lipid formulations as an alternative preferred when renal function is impaired. Current DHHS/NIH/CDC-IDSA opportunistic-infection guidance and WHO now prefer liposomal amphotericin B for lower nephrotoxicity; WHO endorses a single high-dose liposomal amphotericin B strategy given with flucytosine and fluconazole where feasible.
• Fluconazole substitutes for flucytosine only when flucytosine is unavailable — an inferior fallback, not a choice.

Consolidation and maintenance

• Azole: fluconazole at consolidation dosing for ~8 weeks after documented CSF sterilization, then lower-dose secondary prophylaxis for at least 1 year, stopped per DHHS-OI criteria only after sustained CD4 recovery and virologic suppression on ART.

Timing of ART

• Defer ART roughly 4–6 weeks after antifungal initiation (DHHS-OI guidance, informed by the COAT trial); starting ART within the first 1–2 weeks increases mortality from IRIS.

Procedural/definitive

• CSF diversion: lumbar drain or ventriculoperitoneal shunt for refractory ICP or hydrocephalus, appropriate even with CSF not yet sterile.

Contraindicated / avoid

• Corticosteroids as adjunctive therapy — harmful in HIV-associated CM (CryptoDex).
• Mannitol and acetazolamide for ICP control — not recommended.
• Echinocandins — Cryptococcus is intrinsically resistant despite possessing β-1,3-glucan synthase, so caspofungin and micafungin have no role.

Disease-related

• Refractory intracranial hypertension and herniation — EMERGENCY: gelatinous polysaccharide-laden CSF obstructs arachnoid granulation absorption while yeast burden drives edema. Signalled by worsening headache despite therapy, vomiting, declining consciousness, or a Cushing response; herniation itself is a clinical and radiographic diagnosis, while a high opening pressure documents the hypertension. Obtain neuroimaging before LP when focal deficits, seizures, papilledema, or a mass lesion are suspected. Communicating hypertension is managed with immediate therapeutic LP and serial drainage; obstructive (non-communicating) hydrocephalus requires ventricular drainage rather than serial LPs.
• Irreversible blindness and deafness: sustained pressure transmitted along the optic nerve sheath plus direct perineural invasion. Papilledema, enlarging blind spot, or new hearing loss are the sentinel findings — visual loss can occur within days and is often permanent.
• Communicating hydrocephalus: ventriculomegaly on imaging with persistently high opening pressure; often needs a shunt.
• Cryptococcoma with mass effect or seizure: enlarging nodular lesion, focal deficit, or new-onset seizure mandates neuroimaging.
• Cerebral vasculitis and infarction: basilar inflammation of perforating vessels producing focal stroke syndromes.
• Persistent infection vs relapse: CSF cultures that remain positive at the end of 2 weeks of induction indicate an inadequate fungicidal response and mandate prolonging induction and rechecking cultures; IDSA defines persistent infection as positive CSF cultures after ≥4 weeks of appropriate therapy. Relapse after completed therapy raises azole resistance or non-adherence.

Treatment-related

• Immune reconstitution inflammatory syndrome — potentially an emergency: recovering CD4 T cells attack residual antigen after ART. Clinical worsening with rising CSF pleocytosis and pressure but sterile cultures distinguishes it from failure; severe cases with mass effect may require corticosteroids (in contrast to routine adjunctive steroids, which are harmful).
• Amphotericin B nephrotoxicity: afferent arteriolar vasoconstriction plus distal tubular injury → rising creatinine, hypokalemia, hypomagnesemia, and distal (type 1) renal tubular acidosis. Also normocytic anemia from reduced erythropoietin and infusion-related rigors.
• Flucytosine myelosuppression and hepatotoxicity: 5-FU accumulation, worsened by renal impairment; cytopenias on CBC are the signal, so flucytosine dosing must track renal function.
• Fluconazole effects: transaminitis, QT prolongation, and CYP-mediated interactions with antiretrovirals.

• The buzzword pair: India ink clear halo around narrow-based budding yeast, and mucicarmine staining the capsule red on tissue. Soap-bubble lesions in the basal ganglia (dilated perivascular spaces packed with yeast) is the classic imaging descriptor.
• Best initial test is the cryptococcal antigen (CrAg) lateral flow assay, not India ink — CrAg is near-100% sensitive in CSF and serum, whereas India ink misses a substantial minority of cases.
• The single most-tested next step: measure and record the CSF opening pressure, and drain if it is elevated. Examiners reward recognising that repeat therapeutic LPs — not mannitol, not acetazolamide, not steroids — are the treatment for cryptococcal intracranial hypertension.
• Induction always includes amphotericin B plus flucytosine; fluconazole monotherapy is never the right induction answer. (The WHO single high-dose liposomal amphotericin B regimen adds fluconazole to that pair, but never replaces it.) Fluconazole alone belongs in consolidation and maintenance.
• **Echinocandins (caspofungin, micafungin) are inactive against *Cryptococcus*** — intrinsic resistance despite the organism possessing β-1,3-glucan synthase — the most common pharmacology distractor on the topic.
• Do not start ART immediately. Deferring ART several weeks (DHHS-OI guidance) reduces mortality from IRIS; "start ART today" in a newly diagnosed CM patient is a trap.
• Association to know: CD4 <100 cells/µL, pigeon droppings/soil exposure, and urease-positive, phenol-oxidase (melanin)-producing yeast growing on birdseed (Niger) agar as brown colonies.
• The CSF paradox: profoundly immunosuppressed patients can have near-acellular CSF with normal glucose and protein despite enormous fungal burden — a bland CSF never excludes CM. Conversely, C. gattii classically infects immunocompetent hosts (Pacific Northwest) and is more likely to form cryptococcomas.
• Adjunctive dexamethasone is harmful in HIV-associated CM — a deliberate contrast with bacterial (pneumococcal) and tuberculous meningitis, where steroids help.